

參考資料

1. Hong Kong Cancer Registry, Hospital Authority. Female Breast Cancer in 2020. Published October 2022. Accessed August 2, 2023. https://www3.ha.org.hk/cancereg/pdf/factsheet/2020/breast_2020.pdf
2. International Agency for Research on Cancer (IARC). *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 98. Painting, Firefighting, and Shiftwork*. Lyon: International Agency for Research on Cancer; 2010.
3. IARC. List of classifications by cancer sites with sufficient or limited evidence in humans, IARC Monographs Volumes 1 to 134. Updated July 19, 2023. Accessed August 2, 2023. https://monographs.iarc.who.int/wp-content/uploads/2019/07/Classifications_by_cancer_site.pdf
4. Papantoniou K, Castaño-Vinyals G, Espinosa A, et al. Breast cancer risk and night shift work in a case-control study in a Spanish population. *Eur J Epidemiol*. 2016;31(9):867-878. doi:10.1007/s10654-015-0073-y
5. Census and Statistics Department (HK). 2022 Report on Annual Earnings and Hours Survey. Published March 2023. Accessed August 2, 2023. https://www.censtatd.gov.hk/en/data/stat_report/product/B1050014/att/B10500142022AN22B0100.pdf
6. Hvidberg L, Pedersen AF, Wulff CN, Vedsted P. Cancer awareness and socio-economic position: Results from a population-based study in Denmark. *BMC Cancer*. 2014;14(1):581. doi:10.1186/1471-2407-14-581
7. Gürdal SÖ, Saraçoğlu GV, Oran EŞ, Yankol Y, Soybir GR. The effects of educational level on breast cancer awareness: A cross-sectional study in Turkey. *Asian Pacific J Cancer Prev*. 2012;13(1):295-300. doi:10.7314/APJCP.2012.13.1.295
8. Yeung MPS, Chan EYY, Wong SYS, Yip BHK, Cheung PSY. Hong Kong female's breast cancer awareness measure: Cross-sectional survey. *World J Clin Oncol*. 2019;10(2):98-109. doi:10.5306/wjco.v10.i2.98
9. Hong Kong Breast Cancer Foundation. *Hong Kong Breast Cancer Registry Bulletin Issue 2: Socio-Economic Disparities in Breast Cancer Screening Practice and Cancer Staging in Hong Kong*. Hong Kong Breast Cancer Foundation; 2012.
10. Senie RT, Saftlas AF, Brinton LA, Hoover RN. Is breast size a predictor of breast cancer risk or the laterality of the tumor? *Cancer Causes Control*. 1993;4(3):203-208. doi:10.1007/BF00051314
11. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). *Cancer Causes Control*. 1995;6(5):431-438. doi:10.1007/BF00052183
12. Egan KM, Newcomb PA, Titus-Ernstoff L, et al. The relation of breast size to breast cancer risk in postmenopausal women (United States). *Cancer Causes Control*. 1999;10(2):115-118. doi:10.1023/A:1008801131831
13. Ooi BNS, Loh H, Ho PJ, et al. The genetic interplay between body mass index, breast size and breast cancer risk: A Mendelian randomization analysis. *Int J Epidemiol*. 2019;48(3):781-794. doi:10.1093/ije/dyz124
14. del Carmen MG, Halpern EF, Kopans DB, et al. Mammographic breast density and race. *AJR Am J Roentgenol*. 2007;188(4):1147-1150. doi:10.2214/AJR.06.0619

15. National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. Updated March 29, 2023. Accessed August 11, 2023. <https://www.cancer.gov/types/breast/breast-changes/dense-breasts>
16. Non-communicable Disease Branch, Centre for Health Protection, Department of Health (HK). Report of Population Health Survey 2020-22 (Part I). Published December 2022. Accessed August 16, 2023. https://www.chp.gov.hk/files/pdf/dh_phs_2020-22_part_1_report_eng_rectified.pdf
17. Cancer: Breast cancer. In: U.S. Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014:230.
18. Hong Kong Breast Cancer Foundation. *Hong Kong Breast Cancer Registry Bulletin Issue 9: Risk factors for breast cancer in Hong Kong women: A case-control study*. Hong Kong Breast Cancer Foundation; 2018.
19. World Cancer Research Fund / American Institute for Cancer Research. Diet, nutrition, physical activity and breast cancer. *Continuous Update Project Expert Report 2018*. Published May 2018. Accessed August 11, 2023. <https://www.wcrf.org/wp-content/uploads/2021/02/Breast-cancer-report.pdf>
20. Non-communicable Disease Branch, Centre for Health Protection, Department of Health (HK). Report of Health Behaviour Survey 2018/19. Published June 2020. Accessed August 16, 2023. https://www.chp.gov.hk/files/pdf/report_of_health_behaviour_survey_2018_en.pdf
21. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. *PLoS One*. 2012;7(12):e51446. doi:10.1371/journal.pone.0051446
22. Centre for Health Protection, Department of Health (HK). Body Mass Index (BMI) Distribution. Updated December 19, 2017. Accessed August 11, 2023. <https://www.chp.gov.hk/en/statistics/data/10/280/6621.html>
23. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *Lancet*. 2001;358(9291):1389-1399. doi:10.1016/S0140-6736(01)06524-2
24. Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: A systematic review and meta-analysis. *Int J Cancer*. 1997;71(5):800-809. doi:10.1002/(sici)1097-0215(19970529)71:5<800::aid-ijc18>3.0.co;2-b
25. Kwong A, Shin VY, Ho JCW, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *J Med Genet*. 2016;53:15-23. doi:10.1136/jmedgenet-2015-103132
26. Kwong A, Shin VY, Au CH, et al. Detection of germline mutation in hereditary breast and/or ovarian cancers by next-generation sequencing on a four-gene panel. *J Mol Diagn*. 2016;18(4):580-594. doi:10.1016/j.jmoldx.2016.03.005
27. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: A meta-analysis. *BMC Cancer*. 2012;12:197. doi:10.1186/1471-2407-12-197
28. Caini S, Boniol M, Botteri E, et al. The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. *J Dermatol Sci*. 2014;75(1):3-9. doi:10.1016/j.jdermsci.2014.02.007



29. Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. *BMC Cancer*. 2014;14:94. doi:10.1186/1471-2407-14-94
30. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study. *BMC Cancer*. 2011;11:83. doi:10.1186/1471-2407-11-83
31. Chuang SC, Scélo G, Lee YCA, et al. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer*. 2010;102(7):1190-1195. doi:10.1038/sj.bjc.6605616
32. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. *J Clin Oncol*. 2009;27(6):967-973. doi:10.1200/JCO.2008.18.4549
33. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: A meta-analysis. *J Cancer Res Clin Oncol*. 2011;137:1053-1060. doi:10.1007/s00432-011-0979-z
34. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*. 1996;347(9017):1713-1727. doi:10.1016/S0140-6736(96)90806-5
35. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017;377(23):2228-2239. doi:10.1056/NEJMoa1700732
36. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: Case-control study. *PLoS Med*. 2012;9(3):e1001182. doi:10.1371/journal.pmed.1001182
37. Li CI, Beaver EF, Tang MTC, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. *Cancer Res*. 2012;72(8):2028-2035. doi:10.1158/0008-5472.CAN-11-4064
38. Sweeney C, Giuliano AR, Baumgartner KB, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. *Int J Cancer*. 2007;121(11):2517-2523. doi:10.1002/ijc.22970
39. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. *Am J Epidemiol*. 2000;151(4):396-403. doi:10.1093/oxfordjournals.aje.a010219
40. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception*. 2004;69(5):353-360. doi:10.1016/j.contraception.2003.12.015
41. Department of Health (HK). LC Paper No. CB(2)1269/19-20(03) Legislative Council Panel on Health Services. Breast Cancer Screening. Issued July 6, 2020. Accessed August 11, 2023. <https://www.legco.gov.hk/yr19-20/english/panels/hs/papers/hs20200710cb2-1269-3-e.pdf>
42. Breast Cancer Screening Pilot Programme to be launched on September 6 (with photos). HKSAR Government Press Releases. Published September 2, 2021. Accessed August 15, 2023. <https://www.info.gov.hk/gia/general/202109/02/P2021090100619.htm>

43. Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL. Self-detection remains a key method of breast cancer detection for U.S. women. *J Womens Health (Larchmt)*. 2011;20(8):1135-1139. doi:10.1089/jwh.2010.2493
44. Ernst MF, Roukema JA, Coebergh JW, et al. Breast cancers found by screening: Earlier detection, lower malignant potential or both? *Breast Cancer Res Treat*. 2002;76(1):19-25. doi:10.1023/A:1020213817562
45. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: A systematic review. *Lancet*. 1999;353(9159):1119-1126. doi:10.1016/S0140-6736(99)02143-1
46. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer (Version 5.2020). Published July 2020.
47. Amin MB, Edge S, Greene F, et al. (eds). *AJCC Cancer Staging Manual (8th Edition)*. New York, NY: Springer International Publishing; 2017.
48. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med*. 2018;142(11):1364-1382. doi:10.5858/arpa.2018-0902-SA
49. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304
50. Genomic Health. About the Oncotype DX Breast Recurrence Score® Test. Accessed August 11, 2023. <https://www.oncotypeiq.com/en-US/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test>
51. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med*. 2015;13:195. doi:10.1186/s12916-015-0439-8